<p>GatePass Capital LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第四季度购买了 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的新头寸。该公司购买了 360,000 股该公司的股票，价值约为 1,282,000 美元。截至其最近的 SEC 文件，GatePass Capital LLC 持有 Oncology Institute 0.37% 的股份。</p>
<p>获取 <strong>Oncology Institute</strong> 的提醒：</p>
<p>其他几家对冲基金也调整了对 TOI 的持股。高盛集团在第一季度购买了价值 131,000 美元的 Oncology Institute 新头寸。Geode Capital Management LLC 在第二季度将其在 Oncology Institute 的持股增加了 231.7%。Geode Capital Management LLC 目前持有 1,279,443 股该公司的股票，价值 2,623,000 美元，此前在此期间又购买了 893,696 股。Cetera Investment Advisers 在第二季度将其在 Oncology Institute 的持股增加了 35.0%。Cetera Investment Advisers 目前持有 17,545 股该公司的股票，价值 36,000 美元，此前在此期间又购买了 4,545 股。摩根大通在第二季度将其在 Oncology Institute 的持股增加了 51,631.5%。摩根大通目前持有 27,935 股该公司的股票，价值 57,000 美元，此前在此期间又购买了 27,881 股。最后，纽约州共同退休基金在第二季度购买了价值 92,000 美元的 Oncology Institute 新头寸。目前，36.86% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级调整</h2>
<p>最近，一些研究分析师对 TOI 股票发布了报告。Weiss Ratings 在 4 月 20 日的报告中重申了对 Oncology Institute 股票的 &#34;卖出 (d-)&#34; 评级。B. Riley Financial 在 3 月 13 日的报告中将 Oncology Institute 的目标价格从 6.00 美元上调至 8.00 美元，并给予该公司 &#34;买入&#34; 评级。Needham &amp; Company LLC 在 3 月 9 日的报告中重申了 &#34;买入&#34; 评级，并对 Oncology Institute 股票设定了 5.00 美元的目标价格。最后，BTIG Research 在 3 月 9 日的报告中重申了 &#34;买入&#34; 评级，并对 Oncology Institute 股票设定了 7.00 美元的目标价格。四位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，共识目标价格为 7.00 美元。</p>
<p><strong>阅读我们关于 TOI 的最新研究报告</strong></p>
<h2>Oncology Institute 的内部交易</h2>
<p>在其他消息中，董事 Mohit Kaushal 于 4 月 16 日出售了 38,433 股 Oncology Institute 股票。该股票的平均售价为 3.50 美元，总交易额为 134,515.50 美元。出售后，该董事在公司中持有 172,583 股，价值约为 604,040.50 美元。此次交易使其持股减少了 18.21%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，主要股东 Jorey Chernett 于 5 月 20 日购买了 33,500 股该公司的股票。该股票的平均购买价格为每股 4.07 美元，总交易额为 136,345.00 美元。交易后，内部人士直接持有 10,567,858 股该公司的股票，价值约为 43,011,182.06 美元。这代表其持股增加了 0.32%。该购买的披露信息可在 SEC 文件中找到。内部人士在上个季度购买了价值 2,038,896 美元的 637,485 股公司股票。内部人士持有该公司 8.50% 的股份。</p>
<h2>Oncology Institute 股票表现</h2>
<p>TOI 周二开盘价为 4.59 美元。该公司的 50 天简单移动平均线为 3.54 美元，200 天简单移动平均线为 3.33 美元。The Oncology Institute, Inc. 的一年低点为 2.02 美元，一年高点为 4.88 美元。该股票的市值为 4.5368 亿美元，市盈率为 -12.41，贝塔值为 0.33。</p>
<p>Oncology Institute (NASDAQ:TOI - 获取免费报告) 最近一次发布财报是在 5 月 7 日。该公司报告季度每股收益为 ($0.02)，超出分析师共识预期的 ($0.07) 0.05 美元。该公司季度收入为 1.4744 亿美元，而分析师预期为 1.4210 亿美元。平均而言，股票研究分析师预测 The Oncology Institute, Inc. 本财年将发布 -0.2 的每股收益。</p>
<h2>Oncology Institute 简介</h2>
<p>(免费报告)</p>
<p>The Oncology Institute, Inc. 是一家肿瘤学公司，在美国提供各种医疗肿瘤学服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理设置相关的其他护理交付模式；并为一系列制药和医疗设备公司进行临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Oncology Institute</li>
<li>SpaceX 引起关注，但这四只股票可能带来回报</li>
<li>微软股票折扣可能结束，因 AI 催化剂增加</li>
<li>服装收益赢家和输家：拉尔夫·劳伦起飞</li>
<li>为什么沃尔玛、塔吉特和 TJX 在财报后反应如此不同</li>
</ul>
<p><strong>想看看其他对冲基金持有 TOI 的情况吗？</strong> 访问 HoldingsChannel.com 获取 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Oncology Institute 吗？</h2>
<p>在考虑 Oncology Institute 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oncology Institute 并不在名单上。</p>
<p>虽然 Oncology Institute 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>GatePass Capital LLC 已投资 128 万美元于 The Oncology Institute, Inc.，通过收购 360,000 股。其他对冲基金也调整了在 TOI 的持股。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，目标价为 7.00 美元。该股票开盘价为 4.59 美元，市值为 4.5368 亿美元。The Oncology Institute 报告的收益超出预期，上一季度的收入为 1.4744 亿美元</p>

<p>GatePass Capital LLC purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm purchased 360,000 shares of the company's stock, valued at approximately $1,282,000. GatePass Capital LLC owned 0.37% of Oncology Institute as of its most recent SEC filing.</p>
<div class="lb-trans"><p>GatePass Capital LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第四季度购买了 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的新头寸。该公司购买了 360,000 股该公司的股票，价值约为 1,282,000 美元。截至其最近的 SEC 文件，GatePass Capital LLC 持有 Oncology Institute 0.37% 的股份。</p>
</div><p>Get <strong>Oncology Institute</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oncology Institute</strong> 的提醒：</p>
</div><p>Several other hedge funds have also modified their holdings of TOI. Goldman Sachs Group Inc. purchased a new position in Oncology Institute in the first quarter valued at $131,000. Geode Capital Management LLC boosted its holdings in Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after purchasing an additional 893,696 shares during the period. Cetera Investment Advisers boosted its holdings in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares during the period. JPMorgan Chase &amp; Co. boosted its holdings in Oncology Institute by 51,631.5% in the second quarter. JPMorgan Chase &amp; Co. now owns 27,935 shares of the company's stock valued at $57,000 after purchasing an additional 27,881 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in Oncology Institute in the second quarter valued at $92,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金也调整了对 TOI 的持股。高盛集团在第一季度购买了价值 131,000 美元的 Oncology Institute 新头寸。Geode Capital Management LLC 在第二季度将其在 Oncology Institute 的持股增加了 231.7%。Geode Capital Management LLC 目前持有 1,279,443 股该公司的股票，价值 2,623,000 美元，此前在此期间又购买了 893,696 股。Cetera Investment Advisers 在第二季度将其在 Oncology Institute 的持股增加了 35.0%。Cetera Investment Advisers 目前持有 17,545 股该公司的股票，价值 36,000 美元，此前在此期间又购买了 4,545 股。摩根大通在第二季度将其在 Oncology Institute 的持股增加了 51,631.5%。摩根大通目前持有 27,935 股该公司的股票，价值 57,000 美元，此前在此期间又购买了 27,881 股。最后，纽约州共同退休基金在第二季度购买了价值 92,000 美元的 Oncology Institute 新头寸。目前，36.86% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research analysts recently issued reports on TOI shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a report on Monday, April 20th. B. Riley Financial lifted their target price on Oncology Institute from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 13th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Finally, BTIG Research reiterated a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.00.</p>
<div class="lb-trans"><p>最近，一些研究分析师对 TOI 股票发布了报告。Weiss Ratings 在 4 月 20 日的报告中重申了对 Oncology Institute 股票的 &#34;卖出 (d-)&#34; 评级。B. Riley Financial 在 3 月 13 日的报告中将 Oncology Institute 的目标价格从 6.00 美元上调至 8.00 美元，并给予该公司 &#34;买入&#34; 评级。Needham &amp; Company LLC 在 3 月 9 日的报告中重申了 &#34;买入&#34; 评级，并对 Oncology Institute 股票设定了 5.00 美元的目标价格。最后，BTIG Research 在 3 月 9 日的报告中重申了 &#34;买入&#34; 评级，并对 Oncology Institute 股票设定了 7.00 美元的目标价格。四位股票研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 &#34;适度买入&#34;，共识目标价格为 7.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on TOI</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TOI 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Oncology Institute</h2>
<div class="lb-trans"><h2>Oncology Institute 的内部交易</h2>
</div><p>In other news, Director Mohit Kaushal sold 38,433 shares of Oncology Institute stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the sale, the director owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 33,500 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the transaction, the insider directly owned 10,567,858 shares of the company's stock, valued at approximately $43,011,182.06. This represents a 0.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 637,485 shares of company stock worth $2,038,896 in the last quarter. Insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事 Mohit Kaushal 于 4 月 16 日出售了 38,433 股 Oncology Institute 股票。该股票的平均售价为 3.50 美元，总交易额为 134,515.50 美元。出售后，该董事在公司中持有 172,583 股，价值约为 604,040.50 美元。此次交易使其持股减少了 18.21%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，主要股东 Jorey Chernett 于 5 月 20 日购买了 33,500 股该公司的股票。该股票的平均购买价格为每股 4.07 美元，总交易额为 136,345.00 美元。交易后，内部人士直接持有 10,567,858 股该公司的股票，价值约为 43,011,182.06 美元。这代表其持股增加了 0.32%。该购买的披露信息可在 SEC 文件中找到。内部人士在上个季度购买了价值 2,038,896 美元的 637,485 股公司股票。内部人士持有该公司 8.50% 的股份。</p>
</div><h2>Oncology Institute Stock Performance</h2>
<div class="lb-trans"><h2>Oncology Institute 股票表现</h2>
</div><p>TOI opened at $4.59 on Tuesday. The business's 50-day simple moving average is $3.54 and its 200-day simple moving average is $3.33. The Oncology Institute, Inc. has a one year low of $2.02 and a one year high of $4.88. The stock has a market capitalization of $453.68 million, a P/E ratio of -12.41 and a beta of 0.33.</p>
<div class="lb-trans"><p>TOI 周二开盘价为 4.59 美元。该公司的 50 天简单移动平均线为 3.54 美元，200 天简单移动平均线为 3.33 美元。The Oncology Institute, Inc. 的一年低点为 2.02 美元，一年高点为 4.88 美元。该股票的市值为 4.5368 亿美元，市盈率为 -12.41，贝塔值为 0.33。</p>
</div><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. On average, equities research analysts forecast that The Oncology Institute, Inc. will post -0.2 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Oncology Institute (NASDAQ:TOI - 获取免费报告) 最近一次发布财报是在 5 月 7 日。该公司报告季度每股收益为 ($0.02)，超出分析师共识预期的 ($0.07) 0.05 美元。该公司季度收入为 1.4744 亿美元，而分析师预期为 1.4210 亿美元。平均而言，股票研究分析师预测 The Oncology Institute, Inc. 本财年将发布 -0.2 的每股收益。</p>
</div><h2>Oncology Institute Profile</h2>
<div class="lb-trans"><h2>Oncology Institute 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p>
<div class="lb-trans"><p>The Oncology Institute, Inc. 是一家肿瘤学公司，在美国提供各种医疗肿瘤学服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理设置相关的其他护理交付模式；并为一系列制药和医疗设备公司进行临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Oncology Institute</li>
<li>SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns</li>
<li>Microsoft Stock Discount May Be Ending as AI Catalysts Build</li>
<li>Apparel Earnings Winners and Losers: Ralph Lauren Takes Off</li>
<li>Why Walmart, Target and TJX Got Such Different Reactions After Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Oncology Institute</li>
<li>SpaceX 引起关注，但这四只股票可能带来回报</li>
<li>微软股票折扣可能结束，因 AI 催化剂增加</li>
<li>服装收益赢家和输家：拉尔夫·劳伦起飞</li>
<li>为什么沃尔玛、塔吉特和 TJX 在财报后反应如此不同</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TOI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 TOI 的情况吗？</strong> 访问 HoldingsChannel.com 获取 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TOI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oncology Institute 吗？</h2>
</div><p>Before you consider Oncology Institute, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oncology Institute 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oncology Institute 并不在名单上。</p>
</div><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oncology Institute 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

GatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOI

Market Beat

Oncology Institute

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普医疗保健服务 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普全球医疗股指数 ETF - iShares

美国医疗保健供应商 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

高盛

摩根大通

Oncology Institute - CW22

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

GatePass Capital LLC 向 The Oncology Institute, Inc. $TOI 投资了 128 万美元